|Title:||Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor|
|Abstract:||Taxol (I) is a complex deterpene which is currently considered the most exciting lead in cancer chemotherapy. Taxol possesses high cytotoxicity and strong antitumor activity against different cancers which have not been effectively treated by existing antitumor drugs. However, taxol has a problem with solubility in aqueous media, which may impose some serious limitation in its use. Taxotere (III) seems to have antitumor activity superior to taxol with better bioavailability. Taxotere has a modified taxol structure with a modified C-13 side chain. This fact strongly indicates that modification on the C-13 side chain would provide a new series of taxol and Taxotere analogues which may have higher potency, better bioavailability and less unwanted toxicity. The present invention provides efficient and practical methods for the syntheses of Taxotere and its analogues through .beta.-lactam intermediates and their coupling with baccatin III.|
|Inventor(s):||Ojima; Iwao (Port Jefferson, NY)|
|Assignee:||The State University of New York at Stony Brook (Stony Brook, NY)|
|Filing Date:||Feb 29, 2000|
|Claims:||1. A process for the preparation of a metallized baccatin III derivative of the formula ##STR16## |
M is an alkali metal or alkaline earth metal atom (ion), comprising metallizing the corresponding baccatin III compound by reacting said baccatin III compound with a coupling agent, wherein said coupling agent is an alkali metal alkyl disilazide; and wherein
G.sub.2 is acetyl, or a hydroxyl protecting group; and
G.sub.3 is a hydroxyl protecting group.
2. The process according to claim 1, further comprising reacting a .beta.-lactam with said metallized baccatin III derivative to form a taxane.
3. The process of claim 1, wherein:
G.sub.2 is acetyl, or 2,2,2-trichloroethoxy-carbonyl (Troc);
G.sub.3 is 2,2,2-trichloroethoxycarbonyl (troc), or a silyl group selected from trimethylsilyl, triethylsilyl, tripropylsilyl, dimethylethylsilyl, dimethylphenylsilyl, dimethyl(t-butyl)silyl, diethylmethylsilyl, and diphenylmethylsilyl.
4. The process according to claim 2, further comprising deprotecting one or more hydroxyl groups on the taxane.
5. The process according to claim 4, wherein deprotection is accomplished with zinc, acetic acid, and methanol.
6. The process according to claim 5, wherein deprotection is accomplished in approximately 1 hour at 60.degree. C.
7. The process according to any one of claims 1, 2, 3, or 4 wherein the alkali metal alkyl disilazide is at least one compound selected from LiHMDS, NaHMDS, and KHMDS.
8. The process according to claim 7, wherein the at least one compound is NaHMDS.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.